LXRX icon

Lexicon Pharmaceuticals

0.7147 USD
-0.0089
1.23%
At close Dec 20, 4:00 PM EST
Pre-market
0.6400
-0.0747
10.45%
1 day
-1.23%
5 days
-11.77%
1 month
-11.48%
3 months
-56.95%
6 months
-59.16%
Year to date
-55.05%
1 year
-41.42%
5 years
-83.79%
10 years
-88.71%
 

About: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Employees: 285

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

745% more call options, than puts

Call options by funds: $2.34M | Put options by funds: $277K

105% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 22

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

63% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 16

8% more funds holding

Funds holding: 127 [Q2] → 137 (+10) [Q3]

1.93% more ownership

Funds ownership: 77.91% [Q2] → 79.84% (+1.93%) [Q3]

5% less capital invested

Capital invested by funds: $475M [Q2] → $453M (-$22.4M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$6
740%
upside
Avg. target
$6
740%
upside
High target
$6
740%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
21% 1-year accuracy
79 / 384 met price target
740%upside
$6
Buy
Reiterated
13 Nov 2024

Financial journalist opinion

Based on 4 articles about LXRX published over the past 30 days

Negative
Reuters
2 days ago
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
Neutral
GlobeNewsWire
2 days ago
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This expected communication from the FDA aligns with the company's previously disclosed strategic decision to discontinue launch preparations for Zynquista and focus solely on its clinical development pipeline.
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Neutral
GlobeNewsWire
3 weeks ago
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Neutral
GlobeNewsWire
3 weeks ago
Lexicon Pharmaceuticals to Participate in December Investor Conferences
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer and director, will present at two upcoming investor conferences in December.
Lexicon Pharmaceuticals to Participate in December Investor Conferences
Negative
Reuters
1 month ago
Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development
Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development.
Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development
Neutral
GlobeNewsWire
1 month ago
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Neutral
GlobeNewsWire
1 month ago
Lexicon Appoints Ivan H. Cheung to Board of Directors
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors.
Lexicon Appoints Ivan H. Cheung to Board of Directors
Neutral
Seeking Alpha
1 month ago
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Garner - SVP and Chief Commercial Officer Craig Granowitz - SVP and Chief Medical Officer Alan Main - EVP, Innovation and Chemical Sciences Lisa DeFrancesco - Head, IR and Corporate Strategy Conference Call Participants Andrew Tsai - Jeffries Joseph Stringer - Needham and Company Joe Pantginis - H.C. Wainwright Yigal Nochomovitz - Citigroup Roanna Ruiz - Leerink Partners Operator Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2024 Results Conference Call.
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Charts implemented using Lightweight Charts™